tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Corbus Pharmaceuticals transferred with Buy rating at B. Riley

B. Riley kept a Buy rating on Corbus Pharmaceuticals (CRBP) with a $28 price target following a transfer of coverage. The firm believes the company has a “promising” next-generation nectin-4 antibody drug conjugate with the potential to disrupt treatment paradigms in two “underserved” solid tumor types: head and neck and cervical cancer.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1